Profound Medical Corp. PROF
7.21 USD +0.33 (+4.80%)
At closeNov 6, 2026, 4:45 PM EST
7.21 0.00 0.00%
After hours · Nov 6, 4:45 PM ET
6.16 Day range 7.22
4.80 52-week range 8.95
- YTD
- -8.39%
- 1 year
- +23.25%
News
benzinga.com Profound Medical Q3 EPS $(0.21) Misses $(0.19) Estimate, Sales $9.830M Miss $9.867M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 19.23 percent increase over losses of…
zacks.com Profound Medical (PROF) Expected to Beat Earnings Estimates: Should You Buy? Profound Medical (PROF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
zacks.com Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 89.9% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable,…
benzinga.com Profound Medical Strikes Supply, Distribution Deal With iMRI Division Of Cook Medical To Expand Sales Of TULSA-PRO System In U.S. Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI
globenewswire.com Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical's Copernicus™ program, expanding Profound's commercial reach
benzinga.com Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures,- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Profound Medical (NASDAQ:PROF) shares moved upwards by 21.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $207.5 million. Haemonetics (NYSE:HAE) stock…
benzinga.com Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
benzinga.com Profound Medical Reports Q3 Preliminary Revenue Range $9.8M - $10M, Up ~85% To 89% YoY Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
benzinga.com Profound Medical Appoints Richard Fabian As President, Effective Immediately, Succeeding Mathieu Burtnyk Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
benzinga.com Profound Medical Affirms FY2026 Sales Guidance of $25.000M vs $26.858M Est Profound Medical (NASDAQ:PROF) affirms FY2026 sales outlook from $25.000 million to $25.000 million vs $26.858 million estimate.
benzinga.com Profound Medical Q2 EPS $(0.26), Inline, Sales $2.483M Miss $5.500M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.52) per share from the same…
benzinga.com Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and…- benzinga.com Profound Medical Q1 EPS $(0.19) Beats $(0.35) Estimate, Sales $5.337M Miss $6.648M Estimate Profound Medical (TSX:PRN) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 47.22 percent increase over losses of…
benzinga.com Profound Medical To Highlight Interventional MRI TULSA Procedure In Several Presentations At 2026 SIR Annual Scientific Meeting Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
benzinga.com Top 3 Health Care Stocks That Are Set To Fly In March Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strength on up and down days. Here's a list of oversold stocks with RSI near or below 30.- benzinga.com Profound Medical Announces Level 1 Post-Market CAPTAIN Trial Comparing TULSA Procedure With Robotic RP Meets Primary Safety Endpoint In Grade Group 2 And 3 Prostate Cancer – First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment –– TULSA…
benzinga.com Profound Medical Q4 Earnings Assessment 
benzinga.com Earnings Summary: Profound Medical Q4 - benzinga.com Profound Medical Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $5.977M Miss $7.233M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 35 percent decrease over losses of…
benzinga.com Earnings Scheduled For March 5, 2026 
benzinga.com Profound Medical's Earnings: A Preview - benzinga.com Profound Medical Announces First Prostate Cancer Patient Treated With TULSA-PRO At Mount Sinai Hospital Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual functionThe Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World…
- benzinga.com Lake Street Maintains Buy on Profound Medical, Raises Price Target to $12 Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and raises the price target from $11 to $12.
- benzinga.com Profound Medical Announces First Non‑Trial Prostate Cancer Patient Treated With TULSA‑PRO At Johns Hopkins Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
benzinga.com Profound Medical Prices $40M Common Stock Offering Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering…- benzinga.com Profound Medical To Launch TULSA-AI Volume Reduction Module For Optimizing Treatment Of Patients With Benign Prostatic Hyperplasia, Or Enlarged Prostate, At RSNA Meeting Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
- benzinga.com Profound Medical Q3 EPS $(0.26) Beats $(0.36) Estimate, Sales $5.289M Beat $4.995M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.36) by 28.77 percent. This is a 31.58 percent increase over losses of…
- benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com Profound Medical Signs Distribution, Supply Agreement For Its TULSA-PRO System With Getz Healthcare In Australia, New Zealand Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free…
- benzinga.com Profound Medical Enters Into Exclusive Distribution Agreement for TULSA-PRO And Sonalleve With Al Faisaliah Medical Systems In Saudi Arabia Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets artificial intelligence ("AI")-powered, MRI-guided,…
- benzinga.com Profound Medical Regains Exclusive Distribution Rights For TULSA-PRO From Knight Therapeutics In Canada Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets artificial intelligence ("AI")-powered,…
- benzinga.com Profound Medical Projects Q3 Revenue of $5.2M - $5.3M, Up 84% - 87% YoY; Gross Margin Expands To 72% Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for…
- benzinga.com Profound Medical Q2 EPS $(0.52) Misses $(0.35) Estimate, Sales $2.211M Miss $3.533M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.35) by 47.73 percent. This is a 85.71 percent decrease over losses of…
- benzinga.com Earnings Scheduled For August 14, 2025
- benzinga.com Profound Medical Announces First Commercial Use Of TULSA-PRO System's New TULSA-AI Volume Reduction Module For BPH Treatment Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for…
benzinga.com Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket 
benzinga.com Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - benzinga.com Profound Medical Q1 EPS $(0.36) Misses $(0.28) Estimate, Sales $2.62M Miss $3.50M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 38.46 percent decrease over losses of…
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com Profound Medical Announces Initial Perioperative Data From Level 1 Post-Market CAPTAIN Trial Comparing Safety, Efficacy Of TULSA Procedure With RP In Men With Gleason Score 7 Prostate Cancer – First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer –– TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and…
- benzinga.com Lake Street Maintains Buy on Profound Medical, Lowers Price Target to $11 Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target from $17 to $11.
- benzinga.com Profound Medical Q4 EPS $(0.20) Beats $(0.33) Estimate, Sales $4.18M Miss $4.27M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.33) by 39.39 percent. This is a 52.38 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 6, 2025
- benzinga.com Profound Medical Announces Proposed Public Offering Of Common Shares; No Size Or Amount Disclosed BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGARTORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp.…
- benzinga.com Profound Medical Q3 2024 GAAP EPS $(0.38) Misses $(0.30) Estimate, Sales $2.832M Miss $3.006M Estimate Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.30) by 26.67 percent. This is a 46.15 percent decrease over losses of…
- benzinga.com Profound Medical Affirms FY2024 Sales Guidance to $11.00M-12.00M VS Est. $11.23M Profound Medical (NASDAQ:PROF) affirms FY2024 sales outlook from $11.00 million-12.00 million to $11.00 million-12.00 million.